UROLOGIE PRO PRAXI / Urol. praxi. 2025;26(1):17-22 / www.urologiepropraxi.cz 22 PŘEHLEDOVÉ ČLÁNKY Onkologické aspekty urolitiázy technologický výskum pri skúmaní spoločných biomechanických dráh, najmä v kontexte zápalových markerov a dysregulácie reabsorpcie vápnika, poskytne cenné poznatky, ktoré zrejme posunú naše znalosti v tejto oblasti. Dôležité sa ukazuje častejšie využívanie nových zobrazovacích postupov a tiež detailnejšie skúmanie patofyziológie MS. Je potrebné pokračovať v identifikácii prekrývajúcich sa biologických ciest, ktoré možno využiť na ďalšie pochopenie simultánnej detekcie (aj s pomocou zatiaľ nedostatočných molekulárnych postupov) a zlepšenie manažmentu oboch chorôb, ktoré s veľkou pravdepodobnosťou spolu súvisia viac, ako si myslíme. LITERATÚRA 1. Skolarikos A, Jung H, Neisius A, et al. EAU guidelines on urolithiasis. [Internet]. [cited 2024 July 14]. Available from: https:// uroweb.org/guidelines. 2. Scales C, Smith A, Hanley J, et al. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165. 3. Cheungpasitporn W, Thongprayoon C, O´Corragain O, et al. The risk of kidney cancer with patients with kidney stones: a systematic review and meta-analysis. QJM. 2015;108(3): 205-212. 4. Chow W, Lindblad P, Gridley G, et al. Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst. 1997;89(19):1453-1457. 5. Shih C, Chen Y, Ou S, et al. Urinary calculi and risk of cancer: a nationwide population-based study. Medicine (Baltimore). 2014;93(29):e342. 6. Van de Pol J, van den Brandt P, et al. Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands cohort study. Br J Cancer. 2019;120(3):368-374. 7. Warli S, Mantiri B, Sihombing B, et al. Nephrolithiasis – associated renal cell carcinoma in patients who underwent nephrectomy: a single center experience. World J Oncol. 2023;14(1):94-100. 8. Yu Z, Yue W, Jiuzhi L, et al. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. Urolithiasis. 2018;46(6):573-579. 9. Seggard K, Veres K, Norgaard M, et al. Pyelonephritis in persons after age 50 as a clinical marker of urogenital cancer. Clin Microbiol Infect. 2019;25(1):87-91. 10. Lin C, Huang W, Fan W, et al. Associations between interventions for urolithiasis and urinary tract cancer among patients in Taiwan. Medicine. 2016;95:49:e5594. 11. Mihalopoulos M, Yaghoubian A, Razdan S, et al. Understanding thelink between kidney stones and cancers of the upper urinary tract and bladder. Am J Clin Exp Urol. 2022;10(5):277-298. 12. Raghavendran M, Rastogi A, Dubey D, et al. Stones associated renal pelvic malignancies. Indian J Cancer. 2003;40(3):108-112. 13. Peerapen P, Boonmark W, Putpeerawit P, et al. Calcium oxalate crystals trigger epithelial – mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer. Exp Hematol Oncol. 2022;11:62. 14. Shabani F, Farasat A, Mahdavi M, et al. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res. 2018;67(10):801-812. 15. Hu H, Chen D, Wang Y, et al. New insights into TGB-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76-83. 16. Magers M, Kaimakliotis H, Barboza M, et al. Clinico-pathological characteristics ofypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. J Clin Pathol. 2019;72(8):550-553. 17. Bayraktar E, Igci M, Erturhan S, et al. Reduced gene expression of bikunin as a prognostic marker for renal cell carcinoma. Exp Oncol. 2014;36(2):107-111. 18. Blaj V, Li M, Ho S, et al. Design of drug-like hepsin inhibitors against prostate cancer and kidney stones. Acta Pharm Sin B. 2020;10(7):1309-1320. 19. Lu L, Cole A, Huang D, et al. Clinical significance of hepsin and underlying pathways in prostate cancer. Biomolecules. 2022;12(2):203. 20. Damalanka V, Han Z, Karmakar P, et al. Discovery of selective matriptase and hepsin serine protease inhibitors: useful chemical tools for cancer and cell biology. J Med Chem. 2019;62(2):480-490. 21. Schaeffer C, Devuyst O, Rampoldi L. Uromodulin: roles in health and disease. Annu Rev Physiol. 2021;83:477-501. 22. Michaels E, Grosh L, Nakagawa Y, et al. Immunohistochemical localization of nephrocalcin, a kidney-specific glycoprotein, to renal cell carcinoma. Urology. 1988;52(5):920-924. 23. Nakagawa Y. Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Keio J Med. 1997;46(1):1-9. 24. Nie M, Bal M, Yang Z, et al. Mucin-1 increases renal TRPV5 activity in vitro, and urinary levels associates with calcium nephrolithiasis in patients. J Am Soc Nephrol. 2016;27(11): 3447-3458. 25. Yu L, Andrews N, Zhao Q, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2007;282(1):773-781. 26. Mao W, Wang K, Wu Z, et al. Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular. J Exp Clin Cancer Res. 2021;40(1):305. 27. Wang L, Yang G, Zhao D, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote Mir-19b-3p. Mol Cancer. 2019;18(1):86. 28. Singhto N, Kanlaya R, Nilnumkhum A, et al. Roles of macrophage exosomes in immune response to calcium oxalate monohydrate crystals. Fron Immunol. 2018;9:316. 29. Wang Q, Sun Y, Yang Y, et al. Quantitative proteomic analysis of urinary exosomes in kidney stones patients. Transl Androl Urol. 2020;9(4):1572-1584. 30. Hemminki K, Hemminki O, Főrsti A, et al. Familial risks between urolithiasis and cancer. Sci Rep. 2018;8(1):3083. 31. Goldfarb D, Avery A, Beara-Lasic R, et al. A twin study of genetic influences on nephrolithiasis in women and men. Kidney Int Rep. 2018;4(4):535-540. 32. Hemminki K, Hemminki O, Főrsti A, et al. Familial risks in urolithiasis in the population of Sweden. BJU Int. 2018;121(3):479-485. 33. Howles S, Thakker R. Genetics of kidney stone disease. Nat Rev Urol. 2020;17(7):407-421. 34. Sadeghi-Bojd S, Falsafinejad F, Danesh H, et al. Macrophage migration inhibitory factor-173 G>C gene polymorphism is associated with increased risk of nephrotic syndrome in children. Iran J Kidney Dis. 2019;13:232-236. 35. Ma G, Yuan Q, Wang Q, et al. Association between MIF-AS rs755622 and nephrolithiasis risk in Chenise population. Med Sci Monit. 2016;22:563-568. 36. Sun X, Kour B, Wang X, et al. Insights into association between urolithiasis and prostate cancer. J Mens Health. 2021;17(4):52-61. 37. Tang K, Liu H, Jiang K, et al. Predictive value of preoperative inflammatory response biomarkers for metabolic syndrome and post-PCNL systemic inflammatory response syndrome in patients with nephrolithiasis. Oncotarget. 2017;8(49):85612-85627. 38. Spatola L, Ferraro P, Gambaro G, et al. Metabolic syndrome and uric acid nephrolithiasis: insulin resistance in focus. Metabolism. 2018;83:225-233. 39. Uzunlulu M, Telci Kaklili O, Oguz A. Association between metabolic syndrome and cancer. Ann Nutr Metab. 2016;68(3):173-179. 40. Lifshitz K, Ber Y, Margel D. Role of metabolic syndrome in prostate cancer development. Eur Urol Focus. 2021;7:508-512. 41. Wang F, Xu Y. Body mass index and risk of renal cancer: a dose-response meta-analysis of published cohort studies. Int J Cancer. 2014;135(7):1673-1686. 42. Song X, Fan B, Ma C, et al. Clinical research on the correlations between type 2 diabetes mellitus and renal clear cell carcinoma. Zhonghua Wai Ke Za Zhi. 2013;51(7):627-630. 43. Borghi L, Meschi T, Guerra A, et al. Essential arterial hypertension and stone disease. Kidney Int. 1999;55(6):2397-2406. 44. Cupisti A, D´Alessandro C, Samoni S, et al. Nephrolithiasis and hypertension: possible links and clinical implications. J Nephrol. 2014;27(5):477-482. 45. Kim C, Han K, Choi H, et al. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. Hypertension. 2020;75(6):1439-1446. 46. Hidayat K, Du X, Zou S, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. 47. Setiawan V, Stram D, Nomura A, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166(8):932-940. 48. Liu C, Huang S, Wu W, et al. The impact of cigarette smoking, alcohol drinking and betel quid chewing on the risk of calcium urolithiasis. Ann Epidemiol. 2009;19(8):539-545. 49. Soueidan M, Bartlett S, Noureldin Y, et al. Leisure time physical activity, smoking and risk of recent symptomatic urolithiasis: survey of stone clinic patients. Can Urol Assoc J. 2015;9(7-8):257-262. 50. Sun Y, Zhou Q, Zheng J. Nephrotoxic metals of cadmium, lead, mercury and arsenic and the odds of kidney stones in adults: an exposure-response analysis of NHANES 2007–2016. Environ Int. 2019;132:105115. 51. Jones P, Karim Sulaiman S, Gamage K, et al. Do lifestyle factors including smoking, alcohol, and exercise impact your risk of developing kidney stone disease? Outcomes of a systematic review. J Endourol. 2021;35(1):1-7. 52. World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report. Diet, Nutrition, Physical Activity and Kidney Cancer. 2015. [Internet]. Available at: wcrf.org/kidney-cancer-2015. 53. Zhu Y, Horikawa Y, Yang H, et al. BPDE induced lymphocytic chromosome 3p deletions may predict renal cell carcinoma risk. J Urol. 2008;179(6):2416-2421. 54. Lee J, Hunter D, Spiegelman D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies. J Natl Cancer Inst. 2007;99(10):801-810. 55. Wang H, Fan J, Yu C, et al. Consumption of tea, alcohol and fruits and risk of kidney stones: a prospective cohort study in 0.5 million Chinese adults. Nutrients. 2021;13(4):1119. 56. Zaitsu M, Kawachi I, Takeuchi T, et al. Alcohol consumption and risk of upper-tract urothelial cancer. Cancer Epidemiol. 2017;48:36-40. 57. Witjes J, Bruins H, Carrión A, et al. EAU guidelines on muscle invasive and metastatic bladder cancer. [Internet]. [cited 2024 July 14]. Available from: https://uroweb.org/guidelines. 58. Thongboonkert V. Roles for exosome in various kidney diseases and disorders. Fron Pharmacol. 2020;10:1655. 59. Kim M, Hopfer H, Mayr M. Uric acid, kidney disease and nephrolithiasis. Ther Umsch. 2016;73(3):159-165.
RkJQdWJsaXNoZXIy NDA4Mjc=